Supplemental Table 1. Univariate Analysis of Progression-Free and Overall Survival

Supplemental Table 1.Univariate analysis of progression-free and overall survival

Characteristics / PFS (months) / Pvalue / OS (months) / Pvalue
Age / 0.942 / 0.075
Age<65 / 10.8 / 22.2
Age≥65 / 8.0 / 14.8
Sex / 0.257 / 0.116
Male / 10.1 / 19.1
Female / 11.2 / 22.2
Smoking history / 0.474 / 0.263
Never / 11.1 / 22.2
Former/current / 10.1 / 16.0
Performance status / 0.422 / <0.001
ECOG 0-1 / 10.6 / 22.2
ECOG 2-3 / 10.4 / 14.8
Line of EGFR TKIs / 0.512 / 0.699
First-line / 7.2 / 14.8
Secondor more line / 10.6 / 21.8
Stage / 0.388 / 0.687
Postoperative recurrence / 10.4 / 22.1
IIIB / 19.4 / 21.9
IV / 10.6 / 20.7
No. of metastasis at study entry / 0.019 / 0.021
1-2 / 11.9 / 22.2
3-6 / 9.9 / 16.4
Bone metastasis status at study entry / 0.229 / 0.007
Yes / 9.9 / 16.4
No / 11.2 / 23.8
Brain metastasis status at study entry / 0.518 / 0.010
Yes / 10.9 / 19.1
No / 10.4 / 23.8
Type of EGFR mutation / 0.937 / 0.081
Exon 19 deletion / 10.8 / 23.8
L858R mutation / 10.4 / 20.5

PFS progression-free survival, OS overall survival, ECOGEastern Cooperative Oncology Group,EGFRepidermal growth factorreceptor, TKIs tyrosine kinase inhibitors

Supplemental Table 2.Subgroup analysis of patients treated with EGFR TKIs as second-line therapy (n=105)

Characteristics / OS < 22 months
(n=51) / OS≥ 22 months
(n=54) / Pvalue
Age, n (%) / 0.532
Age<65 / 38(74.5) / 43(79.6)
Age≥65 / 13(25.5) / 11(20.4)
Sex, n (%) / 0.664
Male / 21(41.2) / 20(37.0)
Female / 30(58.8) / 34(63.0)
Smoking history, n (%) / 0.692
Never / 37(72.5) / 41(75.9)
Former/current / 14(27.5) / 13(24.1)
Performance status, n (%) / 0.193
ECOG 0-1 / 44(86.3) / 51(94.4)
ECOG 2-3 / 7(13.7) / 3(5.6)
Stage, n (%) / 0.520
Postoperative recurrence / 13(25.5) / 17(31.5)
IIIB / 1(2.0) / 1(1.9)
IV / 37(72.5) / 36(66.7)
No. of metastasis at study entry, n (%) / 0.867
1-2 / 38(74.5) / 41(75.9)
3-6 / 13(25.5) / 13(24.1)
Bone metastasis status at study entry, n (%) / 0.652
Yes / 23(45.1) / 22(40.7)
No / 28(54.9) / 32(59.3)
Brain metastasis status at study entry, n (%) / 0.067
Yes / 25(49.0) / 17(31.5)
No / 26(51.0) / 37(68.5)
EGFR mutation, n (%) / 0.066
Exon 19 deletion / 27(52.9) / 38(70.4)
L858R mutation / 24(47.1) / 16(29.6)

OS overall survival, ECOGEastern Cooperative Oncology Group,EGFRepidermal growth factorreceptor